Comparing end points between cancer patients with and witthout infection.

	Infection	No Infection	P-value
Mean Peak Lactate	4.59 (2.45)	6.42 (4.60)	
24h lactate clearance	58.3%	33.0%	
DOT	12.58 (8.85)	3.25 (3.95)	<0.0001
M D L DOT	27 22 (26 20)	4 50 (0.07)	0.041

Liver involvement affecting Lactate clearance in patients without infection.

	No Infection		
	Liver n=19	No Liver n=14	P-value
Rate of 24h lactate clearance	21%	61.5%	0.033169
DOT	4.53 (4.48)	1.38 (1.98)	0.0246
Mean peak PCT	2.03 (0.61)	0.795 (0.66)	0.0162

**Conclusion:** Cancer patients often manifest SIRS criteria at baseline which may lead to the overdiagnosis of infection and excessive antibiotic usage. Our observation is that lactate clearance as opposed to degree of lactic acidosis may be a more accurate indicator of infection in cancer patients especially those with liver involvement. This information may mitigate unnecessary antibiotic use in cancer patients with persistent lactic acidosis unrelated to infection.

Disclosures: All Authors: No reported disclosures

### 207. Travel Related Risk Behaviors and Antibiotic Use among Older Travelers

Varea H. Costello, D.O.1; David Tribble, MD, DrPH2; Christa Eickhoff, MD3; Drake H. Tilley, MD, MPHT&M<sup>4</sup>; Gregory Utz, MD<sup>5</sup>; Kalyani Telu, MS<sup>6</sup> Anuradha Ganesan, MBBS, MPH<sup>7</sup>; Jamie Fraser, MPH<sup>8</sup>; Tahaniyat Lalani, MBBS<sup>9</sup>; <sup>1</sup>Walter Reed Medical Center, Gaithersburg, Maryland; <sup>2</sup>Uniformed Services University, Bethesda, MD; <sup>3</sup>Naval Medical Center Portsmouth, Portsmouth, Virginia; <sup>4</sup>Naval Medical Center San Diego, San Diego, CA; ⁵Naval Medical Center San Diego, Infectious Disease Clinical Research Program, Bethesda, MD, and Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, MD, San Diego, California; <sup>6</sup>Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD; <sup>7</sup>Infectious Disease Clinical Research Program and the Henry M. Jackson Foundation for the Advancement of Military Medicine and Walter Reed National Military Medical Center, Bethesda, Maryland; <sup>8</sup>Henry M. Jackson Foundation for the Advancement of Military Medicine; Infectious Disease Clinical Research Program, Department of Preventive Medicine & Biostatistics, Uniformed Services University of the Health Sciences, Bethesda, MD; <sup>9</sup>Infectious Disease Clinical Research Program, Bethesda, MD, The Henry M. Jackson Foundation, Bethesda, MD, and Naval Medical Center Portsmouth, VA, Portsmouth, Virginia

## Session: P-7. Antimicrobial Stewardship: Special Populations

**Background:** Older travelers ( $\geq 60$  years) are a unique risk population for travel related infections and adverse events from antibiotics. We evaluated the differences in travel characteristics, exposures, illnesses and antibiotic use among older travelers and those between 18 – 59 y using a prospective, observational cohort of US Department of Defense (DoD) beneficiaries traveling outside the US for  $\leq 6.5$  months (TravMil).

**Methods:** Adult DoD beneficiaries were enrolled pre-travel. Itineraries limited to Western/Northern Europe, Canada, or New Zealand and active duty personnel on military travel were excluded. Demographics, itineraries and prescriptions were abstracted. A post-travel survey collected information on exposures and illnesses (travelers' diarrhea (TD), influenza-like illness (ILI) or febrile illness). Categorical variables were analyzed using chi-square or Fishers exact test and the Mann-U Whitney test was used for continuous variables.

**Results:** Of the 1468 travelers, 755 were ≥ 60y and 719 were < 60y. Asia (35%) and South/Central America (28%) were the most common travel regions. Older travelers were more likely to be Caucasian (80% vs. 67%), male (52% vs. 39%) and travel for tourism (84% vs. 51%) (p< 0.05). Younger travelers were more likely engage in risk behaviors (e.g. consume poorly cooked meat or seafood (16% vs 9%) or street vendor food (26% vs. 8.6%), wade in fresh water (24% vs. 18%), and non-compliance with malaria prophylaxis (22% vs. 12%) (p< 0.05). Older travelers had a lower incidence of TD (18% vs. 24%), and a higher proportion of cases with loose stool or mild TD that did not interfere with daily activities (63% vs. 51%) (p< 0.05). Inappropriate antibiotic use for loose stool or mild TD were similar among the two age groups (67% vs. 59%). Non-significant trends of lower incidence and mild infections were observed for ILI and febrile illness in older travelers.

**Conclusion:** Older travelers were less likely to engage in risk behaviors, had a lower TD incidence and reported mild diarrheal symptoms. Inappropriate antibiotic use for loose stool or mild TD was common in both age groups. Enhancing antibiotic stewardship is important for older travelers to prevent potential side effects, drug interactions and antibiotic resistance.

Disclosures: All Authors: No reported disclosures

#### 208. Variation in Clinical Practice and Attitudes in the Management of Fever and Neutropenia in Patients With Hematologic Malignancy: A Survey of Cancer Centers Across the United States

Samuel L. Aitken, PharmD, MPH, BCIDP<sup>1</sup>; Samuel L. Aitken, PharmD, MPH, BCIDP<sup>1</sup>; Jason N. Barreto, PharmD, BCPS<sup>2</sup>; Jerod Nagel, PharmD<sup>3</sup>; Susan K. Seo, MD<sup>4</sup>; Susan K. Seo, MD<sup>4</sup>; Catherine Liu, MD<sup>5</sup>; <sup>1</sup>The University of Texas MD Anderson Cancer Center, Houston, Texas; <sup>2</sup>Mayo Clinic, Rochester, Minnesota; <sup>3</sup>University of Michigan, Ann Arbor, MI; <sup>4</sup>Memorial Sloan Kettering, New York, New York; <sup>5</sup>Fred Hutchinson Cancer Research Center; University of Washington, Seattle, Washington

### Antimicrobial Stewardship in Cancer Consortium (ASCC)

#### Session: P-7. Antimicrobial Stewardship: Special Populations

**Background:** Fever and neutropenia (FN) is common in cancer patients after chemotherapy, and there are national guideline recommendations for FN prevention and treatment. We conducted a survey of practices across multiple US cancer centers to determine the extent to which these guidelines have been adapted.

Methods: US cancer centers performing 20 allogeneic hematopoietic stem cell transplantations annually were identified from the National Marrow Donor Program's "Be the Match" directory. Antimicrobial stewardship physicians and pharmacists at each institution were identified using institutional websites, residency or fellowship program directories, and personal contacts. A survey assessing institutional practices and individual attitudes on FN management in high-risk patients was distributed via email. Duplicate responses at the hospital level were removed. Complete surveys regarding individual attitudes were assessed using a 5-point Likert scale ranging from "Strongly Agree" to "Strongly Disagree."

**Results:** Thirty-four (23%) responses from 148 individuals were received, representing 31 of 86 hospitals (36%). 29 (94%) hospitals reported having guidelines for the management of FN. Of these, cefepime was the most commonly recommended agent for empiric treatment (26, 90%) and 16 (55%) provide guidance based on presumed site of infection. Eighteen (62%) hospitals recommend de-escalation of Gram negative therapy in certain situations, most often after being afebrile 48 – 72 hours or after neutrophil recovery (7 each, 39%). Twenty-seven (93%) hospitals recommended antibiotic prophylaxis, most often with levofloxacin (21, 78%). Of 34 respondents, attitudes were split regarding the statement "The benefit of antibiotic prophylaxis outweighs the harms in high-risk patients" (10 strongly agree or agree, 10 strongly disagree or disagree; 29% each); most agreed with the statement "I would use antibiotic prophylaxis in high-risk patients" (25, 78%).

**Conclusion:** Most cancer centers across the US have guidelines for the management of FN. While most recommend antibacterial prophylaxis, there were differences in individual perceptions regarding the risk / benefit. Significant variation exists in the approach to antibiotic de-escalation.

Disclosures: All Authors: No reported disclosures

# 209. Antibiotic Utilization During the COVID-19 Surge in Detroit

Anita Shallal, MD<sup>1</sup>; Rachel Kenney, PharmD<sup>1</sup>; Geehan Suleyman, MD<sup>1</sup>; <sup>1</sup>Henry Ford Hospital, Detroit, Michigan

### Session: P-8. Antimicrobial Stewardship: Trends in Antimicrobial Prescribing

Background: Antibiotic overutilization during the COVID-19 pandemic has been reported, despite relatively infrequent bacterial co-infection. We explored antibiotic utilization before, during and after the COVID-19 surge in Michigan.
Methods: Cross-sectional study at an 877-bed hospital in Detroit, Michigan

**Methods:** Cross-sectional study at an 877-bed hospital in Detroit, Michigan from January 2019 through May 2020. Measures: Count of COVID-19 hospital admissions by day. Monthly antibiotic utilization for formulary agents used to treat pneumonia were measured using monthly days of therapy (DOT) per 1000 patient days present and the National Health Care Safety Network Standardized Antimicrobial Administration Ratio (SAAR). Descriptive analysis was utilized.

**Results:** The first COVID-19 case was detected March 11, 2020 and peaked in early April (Figure 1). Antibiotic utilization is demonstrated in Figure 2. The COVID-19 peak was associated with increased use of multiple antibiotics; notably, DOT per 1000 days present for ceftriaxone, cefepime and doxycycline were 85.43, 79.42 and 71.56, respectively in April. The institutional all-antibacterial SAAR was significantly reduced in May at 0.96, p=0.0022, after the COVID-19 surge. Figure 1

Figure 1. COVID Hospitalizations by Day

